Author Archives: Bruno Quinney

Delegates at a conference
#Life sciences #SLAS

SLAS2027 Innovation AveNEW entries open for submissions 

SLAS has announced that applications for SLAS2027 Innovation AveNEW programme are now open.  Part of the SLAS Ignite Program for start-up companies in the life sciences discovery and technology sectors, the competition is now accepting entries until Monday 14 September.  Innovation AveNEW companies who opt-in… Read More

#News

#AI #ASCO #Cancer research #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

DDW Highlights: 30 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers uncovered clues explaining risks of heart disease, lung disease, Covid-19 and… Read More

#Podcasts

#AI #AstraZeneca #Drug discovery #Isomorphic Labs #Pistoia Alliance

From the Editor: The steady shift to AI

It is especially difficult within the life sciences sector – and indeed everyday life – to avoid mentions of AI and the inevitable changes it will bring, and is bringing, to drug discovery.   Further difficulty stems from the need to distinguish between hype, reality and fantasy. Drug discovery and development is a… Read More

#Exclusive Content

Alopecia
#Absci #Alopecia #Clinical trial

Absci reports positive data from Phase I alopecia trial 

Biopharmaceutical company Absci has reported positive data from the Phase I trial of its alopecia treatment.  ABS-201, an investigational anti-prolactin receptor (PRLR) antibody, was evaluated in a first-in-human, randomised, double-blind, placebo-controlled study in 32 healthy volunteers with and without androgenetic alopecia (AGA).  The medication proved to be well-tolerated across… Read More

#News

#Cancer treatment #Cell therapy

Virtual care to support patients receiving cell therapies 

Virtual oncology care platform Reimagine Care and The Center for Cancer and Blood Disorders have partnered to support patients receiving advanced cell therapies.  The Advanced Therapy Management (ATM) programme provides a model designed to support outpatient post-infusion monitoring and management of CAR-T and other advanced oncology therapies.    The expansion builds on… Read More

#News

#Acute Myeloid Leukaemia #Mergers and acquisitions

Thalia acquires Sanmirna and AML RNA therapy 

Biotechnology company Thalia Therapeutics has acquired Sanmirna Therapeutics and its clinical-stage cancer RNA therapy.  The acquisition catapults Thalia to a clinical-stage RNA therapeutics company, leveraging Sanmirna’s anti-microRNA-126 for the treatment of acute myeloid leukaemia.  The deal is believed to be worth £16.675 million ($21.984 million), encompassing an initial consideration of £3.675 million ($4.845… Read More

#Business & Investment #News

Immunotherapy
#Cancer immunotherapy #Cervical cancer #National Institute for Health and Care Excellence (NICE) #Regeneron Pharmaceuticals

NICE recommends immunotherapy to treat cervical cancer 

The National Institute for Health and Care Excellence (NICE) has recommended cemiplimab for the treatment of advanced cervical cancer.  The immunotherapy, developed by biotechnology company Regeneron, has been recommended in England and Wales to treat recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy in adults.   This… Read More

#News #Regulatory

#Covid-19 #Genetic profiling #Lung disease #University of Edinburgh

Genetic variation increases Covid-19 and lung disease risk 

A genetic difference carried by nearly one in three could increase the risk of Covid-19 and lung disease, a new study shows.  Researchers at the University of Edinburgh found the genetic variant alters a newly discovered enzyme found in lung tissue, disrupting the function of a previously unknown protein. This… Read More

#News

Cholesterol test
#Cholesterol #Drug development #Heart disease #University of California San Diego

Hidden pathway could be targeted to reduce heart disease 

A hidden biological pathway could be targeted to reduce cholesterol-related heart disease, research shows.  A team from the University of California San Diego School of Medicine uncovered a biological pathway involving the liver, explaining why high-cholesterol diets impede the body’s ability to clear harmful low-density lipoprotein (LDL)… Read More

#News

Ageing hands
#Bowel cancer #Cancer Grand Challenges #Gastrointestinal cancer #Lung cancer

Faster ageing could be linked to developing cancer 

People who show signs of faster biological ageing could be more likely to develop cancer earlier in life, a new study suggests.  Scientists from the PROSPECT team, funded by Cancer Grand Challenges, analysed blood samples and health information from more than 164,000 people from the UK and… Read More

#Cancer Research #News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Collaboration #Lonza

Lonza and InduPro to collaborate on next-gen ADC therapies 

Lonza and InduPro have signed a licensing agreement to advance next-generation antibody-drug conjugates (ADC) therapies.  Under the terms of the agreement, Lonza will grant InduPro a non-exclusive, worldwide license to its proprietary GlycoConnect, HydraSpace and linker-payload technologies. These technologies will be applied to the development of ADCs targeting up to two oncology antigens, supporting the… Read More

#Business & Investment #Cancer Research #News

Protein degradation
#Protein degradation #Seed funding #TRIMTECH Therapeutics

TRIMTECH raises $47m for protein degradation portfolio 

TRIMTECH Therapeutics has raised an additional $14 million in seed funding, bringing total investment for the company’s targeted protein degradation portfolio to $47 million.  TRIMTECH has demonstrated its TRIMTAC and TRIMGLUE degraders can selectively degrade toxic protein aggregates and oligomers while leaving the functional monomeric forms of these proteins intact to… Read More

#Business & Investment #News

#Cell therapy #Europe #Investment

Cellares extends funding for cell therapy manufacturing 

Cellares has raised $327 million for its cell therapy infrastructure project.  Cellares, which says it is the first Integrated Development and Manufacturing Organization (IDMO), extended its Series D funding thanks to an additional $50 million investment from Prime Radiant Partners.  The investment is set to support the next phase of Cellares’ global Smart Factory… Read More

#Business & Investment #News

Colon cancer
#Colorectal cancer #European Commission #Pierre Fabre Laboratories

EC approves metastatic colorectal cancer combination regimen 

The European Commission (EC) has approved a combination therapy for the treatment of metastatic colorectal cancer.  Braftovi (encorafenib) has been approved in combination with cetuximab and FOLOX for the first-time treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC).  The approval is based on the results from the Phase III BREAKWATER trial, which… Read More

#News #Regulatory